Memphasys Limited (MEM.AX)
Memphasys Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Homebush, NSW, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $21.6M. Its beta of 0.49 implies it has historically moved less than the broad market.
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors. Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures. The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination. Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.
Memphasys Limited is most often compared with the following Healthcare names: